3-苯基-4-吡啶羧酸甲酯 | 850162-87-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-苯基-4-吡啶羧酸甲酯
• 英文名称: phenyl-3 carbomethoxy-4 pyridine
• 英文别名: 3-phenylpyridine-4-carboxylic acid methyl ester；Methyl 3-phenylpyridine-4-carboxylate
• CAS: 850162-87-7
• 化学式: C₁₃H₁₁NO₂
• 分子量: 213.236
• InChiKey: KYTMHPFNGAMHPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-苯基-4-吡啶羧酸甲酯 在 盐酸 、 sodium hydroxide 、 PPA 、 zinc(II) iodide 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 3-aza-9-hydroxy-9-fluorene carboxylic acid methyl ester
  参考文献：
  名称：

  9-Hydroxyazafluorenes and Their Use in Thrombin Inhibitors

  摘要：

  Optimization of a previously reported thrombin inhibitor, 9-hydroxy-9-fluorenylcarbonyl-l-prolyl-trans-4-aminocyclohexylmethylamide (1), by replacing the aminocyclohexyl P1 group provided a new lead structure, 9-hydroxy-9-fluorenylcarbonyl-l-prolyl-2-aminomethyl-5-chlorobenzylamide (2), with improved potency (K(i) = 0.49 nM for human thrombin, 2x APTT = 0.37 microM in human plasma) and pharmacokinetic properties (F = 39%, iv T(1/2) = 13 h in dogs). An effective strategy for reducing plasma protein binding of 2 and improving efficacy in an in vivo thrombosis model in rats was to replace the lipophilic fluorenyl group in P3 with an azafluorenyl group. Systematic investigation of all possible azafluorenyl P3 isomers and azafluorenyl-N-oxide analogues of 2 led to the identification of an optimal compound, 3-aza-9-hydroxyfluoren-9(R)-ylcarbonyl-l-prolyl-2-aminomethyl-5-chlorobenzylamide (19b), with high potency (K(i) = 0.40 nM, 2x APTT = 0.18 microM), excellent pharmacokinetic properties (F = 55%, T(1/2) = 14 h in dogs), and complete efficacy in the in vivo thrombosis model in rats (inhibition of FeCl(3)-induced vessel occlusions in six of six rats receiving an intravenous infusion of 10 microg/kg/min of 19b). The stereochemistry of the azafluorenyl group in 19b was determined by X-ray crystallographic analysis of its N-oxide derivative (23b) bound in the active site of human thrombin.

  DOI：

  10.1021/jm049423s
• 作为产物：
  描述：

  3-溴异烟酸甲酯 、 苯硼酸 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 甲苯 为溶剂， 反应 4.0h， 以80%的产率得到3-苯基-4-吡啶羧酸甲酯
  参考文献：
  名称：

  9-Hydroxyazafluorenes and Their Use in Thrombin Inhibitors

  摘要：

  Optimization of a previously reported thrombin inhibitor, 9-hydroxy-9-fluorenylcarbonyl-l-prolyl-trans-4-aminocyclohexylmethylamide (1), by replacing the aminocyclohexyl P1 group provided a new lead structure, 9-hydroxy-9-fluorenylcarbonyl-l-prolyl-2-aminomethyl-5-chlorobenzylamide (2), with improved potency (K(i) = 0.49 nM for human thrombin, 2x APTT = 0.37 microM in human plasma) and pharmacokinetic properties (F = 39%, iv T(1/2) = 13 h in dogs). An effective strategy for reducing plasma protein binding of 2 and improving efficacy in an in vivo thrombosis model in rats was to replace the lipophilic fluorenyl group in P3 with an azafluorenyl group. Systematic investigation of all possible azafluorenyl P3 isomers and azafluorenyl-N-oxide analogues of 2 led to the identification of an optimal compound, 3-aza-9-hydroxyfluoren-9(R)-ylcarbonyl-l-prolyl-2-aminomethyl-5-chlorobenzylamide (19b), with high potency (K(i) = 0.40 nM, 2x APTT = 0.18 microM), excellent pharmacokinetic properties (F = 55%, T(1/2) = 14 h in dogs), and complete efficacy in the in vivo thrombosis model in rats (inhibition of FeCl(3)-induced vessel occlusions in six of six rats receiving an intravenous infusion of 10 microg/kg/min of 19b). The stereochemistry of the azafluorenyl group in 19b was determined by X-ray crystallographic analysis of its N-oxide derivative (23b) bound in the active site of human thrombin.

  DOI：

  10.1021/jm049423s

文献信息

• Iron-Catalyzed Direct C-H Arylation of Heterocycles and Quinones with Arylboronic Acids
  作者：Arghya Deb、Srimanta Manna、Arun Maji、Uttam Dutta、Debabrata Maiti

  DOI：10.1002/ejoc.201300743

  日期：2013.8

  The arylation of C–H bonds to generate heteroaryl–aryl (Het–Ar) and arylated quinone (Quin–Ar) compounds has received great attention to achieve sustainable goals in synthetic chemistry. Despite significant advances, arylation of a broad range of Het–Ar and Quin–Ar derivatives remains a challenging task. Herein, a variety of heterocycles are arylated by using arylboronic acids in the presence of catalytic

  C-H键的芳基化生成杂芳基-芳基（Het-Ar）和芳基化醌（Quin-Ar）化合物在合成化学中实现可持续目标方面受到了极大的关注。尽管取得了重大进展，广泛的 Het-Ar 和 Quin-Ar 衍生物的芳基化仍然是一项具有挑战性的任务。在本文中，在催化量的廉价 Fe(NO3)3 存在下，使用芳基硼酸将各种杂环芳基化。C-芳基化醌化合物可以通过芳基硼酸与醌或氢醌反应来制备。本方法操作简单，可扩展，不需要杂环或醌的预官能化，并且可以容忍偶联伙伴中的多种官能团。这些品质有望使这种方法对学术和工业用途具有吸引力。
• Decomposition du peroxyde de benzoyle dans des melanges carbomethoxy-4 Pyridine/Benzene
  作者：J. Court、S. Vidal、J.M. Bonnier

  DOI：10.1016/s0040-4020(01)90100-0

  日期：1988.1
• 9-Hydroxyazafluorenes and Their Use in Thrombin Inhibitors
  作者：Kenneth J. Stauffer、Peter D. Williams、Harold G. Selnick、Philippe G. Nantermet、Christina L. Newton、Carl F. Homnick、Matthew M. Zrada、S. Dale Lewis、Bobby J. Lucas、Julie A. Krueger、Beth L. Pietrak、Elizabeth A. Lyle、Rominder Singh、Cynthia Miller-Stein、Rebecca B. White、Bradley Wong、Audrey A. Wallace、Gary R. Sitko、Jacquelyn J. Cook、Marie A. Holahan、Maria Stranieri-Michener、Yvonne M. Leonard、Joseph J. Lynch,、Daniel R. McMasters、Youwei Yan

  DOI：10.1021/jm049423s

  日期：2005.4.1

  Optimization of a previously reported thrombin inhibitor, 9-hydroxy-9-fluorenylcarbonyl-l-prolyl-trans-4-aminocyclohexylmethylamide (1), by replacing the aminocyclohexyl P1 group provided a new lead structure, 9-hydroxy-9-fluorenylcarbonyl-l-prolyl-2-aminomethyl-5-chlorobenzylamide (2), with improved potency (K(i) = 0.49 nM for human thrombin, 2x APTT = 0.37 microM in human plasma) and pharmacokinetic properties (F = 39%, iv T(1/2) = 13 h in dogs). An effective strategy for reducing plasma protein binding of 2 and improving efficacy in an in vivo thrombosis model in rats was to replace the lipophilic fluorenyl group in P3 with an azafluorenyl group. Systematic investigation of all possible azafluorenyl P3 isomers and azafluorenyl-N-oxide analogues of 2 led to the identification of an optimal compound, 3-aza-9-hydroxyfluoren-9(R)-ylcarbonyl-l-prolyl-2-aminomethyl-5-chlorobenzylamide (19b), with high potency (K(i) = 0.40 nM, 2x APTT = 0.18 microM), excellent pharmacokinetic properties (F = 55%, T(1/2) = 14 h in dogs), and complete efficacy in the in vivo thrombosis model in rats (inhibition of FeCl(3)-induced vessel occlusions in six of six rats receiving an intravenous infusion of 10 microg/kg/min of 19b). The stereochemistry of the azafluorenyl group in 19b was determined by X-ray crystallographic analysis of its N-oxide derivative (23b) bound in the active site of human thrombin.